StockNews.com lowered shares of DaVita (NYSE:DVA – Free Report) from a strong-buy rating to a buy rating in a research note issued to investors on Saturday morning.
Other research analysts have also recently issued research reports about the stock. Truist Financial upped their target price on shares of DaVita from $135.00 to $150.00 and gave the stock a hold rating in a research report on Wednesday, May 15th. Barclays upped their target price on shares of DaVita from $133.00 to $150.00 and gave the stock an equal weight rating in a research report on Monday, May 6th. Finally, UBS Group upped their target price on shares of DaVita from $113.00 to $134.00 and gave the stock a buy rating in a research report on Wednesday, February 14th. Two equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of Moderate Buy and a consensus target price of $144.67.
DaVita Stock Performance
Shares of NYSE:DVA traded down $0.66 during trading on Friday, reaching $143.18. 960,553 shares of the company’s stock traded hands, compared to its average volume of 799,268. The company has a debt-to-equity ratio of 7.95, a current ratio of 1.43 and a quick ratio of 1.37. DaVita has a 12 month low of $71.51 and a 12 month high of $147.93. The company has a 50 day moving average of $136.79 and a 200-day moving average of $122.54. The stock has a market capitalization of $12.56 billion, a P/E ratio of 16.27, a price-to-earnings-growth ratio of 1.10 and a beta of 0.96.
DaVita (NYSE:DVA – Get Free Report) last announced its quarterly earnings data on Thursday, May 2nd. The company reported $2.38 earnings per share for the quarter, beating analysts’ consensus estimates of $1.95 by $0.43. DaVita had a net margin of 6.61% and a return on equity of 68.52%. The business had revenue of $3.07 billion during the quarter, compared to the consensus estimate of $3.03 billion. During the same quarter in the prior year, the firm earned $1.58 EPS. The company’s revenue for the quarter was up 6.9% compared to the same quarter last year. On average, equities analysts expect that DaVita will post 9.62 EPS for the current year.
Insider Activity
In related news, Director Barbara J. Desoer sold 5,030 shares of the stock in a transaction that occurred on Friday, May 10th. The shares were sold at an average price of $138.81, for a total transaction of $698,214.30. Following the completion of the sale, the director now directly owns 10,954 shares of the company’s stock, valued at $1,520,524.74. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 2.00% of the company’s stock.
Institutional Trading of DaVita
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Deutsche Bank AG lifted its position in shares of DaVita by 421.8% in the 3rd quarter. Deutsche Bank AG now owns 1,095,081 shares of the company’s stock valued at $103,518,000 after acquiring an additional 885,195 shares in the last quarter. 8 Knots Management LLC purchased a new stake in shares of DaVita in the 4th quarter valued at approximately $89,504,000. Doma Perpetual Capital Management LLC purchased a new stake in shares of DaVita in the 4th quarter valued at approximately $53,076,000. Norges Bank purchased a new stake in shares of DaVita in the 4th quarter valued at approximately $36,626,000. Finally, Invesco Ltd. lifted its position in shares of DaVita by 21.3% in the 3rd quarter. Invesco Ltd. now owns 1,667,255 shares of the company’s stock valued at $157,606,000 after acquiring an additional 292,767 shares in the last quarter. 90.12% of the stock is owned by institutional investors and hedge funds.
DaVita Company Profile
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.